

Author's pre-print version. Original version can be found at <http://goo.gl/husrE>.

Please cite as Arechavala-Gomez et al. Nature Reviews Neurol. doi:10.1038/nrneurol.2012.15-c1

Correspondence

Measuring dystrophin—faster is not necessarily better

Virginia Arechavala-Gomez, Lucy Feng, Jennifer E. Morgan and Francesco Muntoni

A Research Highlight in the February issue (A novel imaging method to quantify low levels of dystrophin in Duchenne muscular dystrophy. *Nat. Rev. Neurol.* **8**, 120; 2012)¹ presented findings on a new method for rapid dystrophin quantification in Duchenne muscular dystrophy (DMD)². Although of interest, we believe that caution is required in the interpretation of dystrophin measurements obtained using this new technique.

DMD is caused by the deficit of dystrophin protein at sarcolemma of muscle fibres³. Quantification of dystrophin on muscle biopsies is the main diagnostic test for DMD when genetic testing is unavailable. Several therapeutic approaches in DMD aim to restore dystrophin expression: redirection of splicing with antisense oligonucleotides;⁴ gene therapy⁵; stem cell therapy;⁷ and nonsense mutation read-through.^{8, 9} Precise quantification of dystrophin protein in muscle biopsies taken before and after treatment is crucial to evaluate the biochemical success of the therapeutic intervention.

Until recently, counting dystrophin positive fibres or western blotting were the only quantitative methods available, but researchers preparing for the first trials developed a method to sensitively quantify dystrophin and other associated proteins in the muscle fibre sarcolemma using only two muscle sections per antibody.¹⁰ The method uses intensity measurements from fluorescently labelled dystrophin antibodies and spectrin labelling as a normalising factor. The technique greatly advanced dystrophin quantification owing to its sensitivity, requirement for very little sample, capacity to confirm the correct localization of the protein at sarcolemma, and accessibility to most pathology laboratories. Despite being labour intensive, this method has been used in the analysis of several clinical trials,^{4, 5} and in human¹¹⁻¹³ and mouse^{14, 15} studies.

Aided by a new spectrin antibody that enabled immunostaining for dystrophin and spectrin on the same section, researchers have been able to automate this technique², which should accelerate the analysis of muscle biopsies in ongoing clinical trials. Despite the unequivocal advance that this method entails, one should note the potential drawbacks. One important aspect is that the original method involves collection of up to 40 data points per section, each corresponding to a muscle fibre, whereas the recent modification involves collecting an average dystrophin intensity of the whole image. For averages or multiple measurements in sections from a manifesting carrier, a clear segregation of measurements is immediately evident using the original method¹⁰, which is lost with the new method (Figure 1a and b).² Similarly, two patients from a recent clinical trial have almost identical levels of dystrophin when assessed using the new

method, whereas the original method shows that the average of one sample is increased due to a few high measurements (Figure 1c).

Some patients have a few intensely dystrophin-positive fibres, whereas others have more dimly dystrophin-positive fibres, which accounts for the variability in dystrophin expression in these trials⁴. To guarantee the optimal evaluation of the response to treatment, it is vital that the maximum amount of information is collected from the very small samples available. As image capture methods do not differ,^{2, 10} only a slight modification of the method to include several measurements per image would suffice.




Figure 1 Comparison of methods for dystrophin quantification. a. Transverse cryosections of quadriceps muscle biopsies, immunostained with a dystrophin antibody. **b.** Intensity profiles of images in a, captured as an average measurement² (left) or with multiple measurements¹⁰ (right). **c.** Two samples from a recent systemic clinical⁴ trial analysed using average measurement (left) and multiple measurement (right) Pre-treatment in blue, post treatment in green.

**The Dubowitz Neuromuscular Centre
University College London Institute of Child Health,
30 Guilford Street,
London, WC1N 1EH**

Correspondence to: V. Arechavala-Gomez

v.arechavala@ucl.ac.uk

Competing interests

The authors declare no competing interests

1. Malpass, K. Neuromuscular disease: A novel imaging method to quantify low levels of dystrophin in Duchenne muscular dystrophy. *Nat Rev Neurol* (2012).

2. Taylor, L.E., Kaminoh, Y.J., Rodesch, C.K. & Flanigan, K.M. Quantification of Dystrophin Immunofluorescence in Dystrophinopathy Muscle Specimens. *Neuropathol Appl Neurobiol* (2012).
3. Hoffman, E.P., Brown, R.H., Jr. & Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* **51**, 919-28 (1987).
4. Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet* **378**, 595-605 (2011).
5. Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *Lancet Neurol* **8**, 918-28 (2009).
6. Mendell, J.R. et al. Dystrophin immunity in Duchenne's muscular dystrophy. *N Engl J Med* **363**, 1429-37 (2010).
7. Patel, K. & Morgan, J. 185th ENMC International Workshop: stem/precursor cells as a therapeutic strategy for muscular dystrophies 3-5 June 2011, Naarden, The Netherlands. *Neuromuscul Disord* **22**, 447-52 (2012).
8. Hirawat, S. et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. *J Clin Pharmacol* **47**, 430-44 (2007).
9. Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. *Ann Neurol* **67**, 771-80 (2010).
10. Arechavala-Gomez, V. et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. *Neuropathol Appl Neurobiol* **36**, 265-74 (2010).
11. Arechavala-Gomez, V. et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. *Neuromuscul Disord* **20**, 295-301 (2010).
12. Cirak, S. et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. *Mol Ther* **20**, 462-7 (2012).
13. Anthony, K. et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. *Brain* **134**, 3547-59 (2011).
14. Malerba, A., Boldrin, L. & Dickson, G. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. *Nucleic Acid Ther* **21**, 293-8 (2011).
15. Malerba, A. et al. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. *Mol Ther* **19**, 345-54 (2011).